AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02638298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dry Gauze Dressing
Description: Standard Dry Gauze Dressing
Study NCT04644861 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Program of adapted physical activity
Description: 3 workouts of one hour every week during 4 months. Program will be conducted by adapted physical activity teachers and sports doctor.
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Combination therapy (Antibiotics + diet)
Description: Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 1- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 2- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study
Study NCT04082559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm 3- Nutritional prevention
Description: Patients in clinical remission will be recruited to a dietary prevention study
Study NCT00608335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT01369615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride controlled-release tablets
Description: Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
Study NCT02676466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
Study NCT02676466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
Study NCT02676466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega-3 fish oil
Description: The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
Study NCT02676466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
Study NCT02676466 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
Study NCT02676466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil (Fish oil Placebo)
Description: The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
Study NCT02676466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Corn Oil (Fish oil Placebo)
Description: The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
Study NCT03409718 — intervention group
Intervention type: DEVICE
Intervention: Biomet Comprehensive Shoulder System
Description: Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
Study NCT01221077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: As of 01 March 2013, OSI-906 is no longer being administered
Study NCT01221077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib administered orally
Study NCT01221077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib administered orally
Study NCT01221077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As of 01 March 2013, the matching placebo is no longer being administered
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT02676466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cellulose Based (Losartan Placebo)
Description: The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
Study NCT02676466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose Based (Losartan Placebo)
Description: The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
Study NCT04624438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with electromyostimulation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The force intensity was determined individually during pretest where EMS was delivered at maximal tolerable dose. Electrical stimulation was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Stimulation characteristics were selected among the Compex commercially available strength programs. The stimulation intensity was monitored on-line and determined by the subject at the start of each EMS session according to his/her pain threshold to produce a force corresponding to at least 60% of the pretest MVC score.
Study NCT04624438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with voluntary activation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). Participants were required to reach the proscribed force level only through voluntary activation of QF. To attain the same contraction/rest ratio as in EMS, automated audible signals were delivered in accordance with the contraction-rest pattern produced by the muscle stimulation device. To ensure participants produced 60% of individual MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
Study NCT04624438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric training with combination of electromyostimulation and voluntary activation
Description: Each training session (18 in total) consisted of forty 4-s contractions separated by 20 s inter-contraction intervals. The exercise intensity was close-to-identical among the sessions (60 %MVC). The proscribed force level was reached by the simultaneous action of EMS and VOLUNTARY. Each contraction was 6.25-second long and was followed by a rest period of 20-second (duty cycle 15%). Electrical stimulation corresponded to 30% of MVC, while the remaining 30% was achieved through voluntary muscle activation. To ensure participants produced a force corresponding to 60% of MVC during each contraction the force level was measured with a force transducer and real-time feedback was provided on a computer screen.
Study NCT03451292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albutein 20% Injectable Solution
Description: Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
Study NCT03451292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
Study NCT03451292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical treatment
Description: Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
Study NCT03283553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist, MyChart, OpenNotes
Description: 1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
Study NCT03283553 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Routine medical oncology care
Study NCT04304469 — intervention group
Intervention type: OTHER
Intervention: surveys
Description: delivery of the survey at a domestic violence consultation
Study NCT04304469 — intervention group
Intervention type: OTHER
Intervention: follow-up
Description: follow-up of women 6 months after their consultation
Study NCT00508976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected bupivacaine post-operatively
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study NCT00508976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streamed bupivacaine versus streamed normal saline
Description: Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study NCT00508976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized bupivacaine versus aerosolized saline
Description: Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study NCT00508976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injected lidocaine pre-incision vs saline pre-incision
Description: Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
Study NCT04555330 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physical activity measurement
Description: To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking.
Study NCT04555330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity measurement
Description: To assess physical activity two small tri-axial accelerometers embedded in medical Band-Aids will be used. The accelerometers are discretely worn on the lateral aspect of the thigh.~The accelerometers sample accelerations continuously during hospitalisation and are connected wirelessly to a tablet that via an inbuilt algorithm classify the recordings as bedridden (lying down), sitting, standing, and walking.
Study NCT04555330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback
Description: The tablet will be placed on the patients bedside table and provides feedback on the amount of physical activity and motivational imagesand texts that will be visible for the patients, the health care staff and visitors.
Study NCT03172624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: nivolumab 3 mg/kg every 2 weeks
Study NCT03172624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
Study NCT01903811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00004228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01903811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT01903811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01231347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
Study NCT01231347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intravenously on days 1 and 15 of a 28 day cycle
Study NCT01231347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
Study NCT01231347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Study NCT01231347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin 4% topical gel formulation:
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin 4% topical gel formulation:
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin 1% lotion formulation:
Description: 7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone tablet (0.5mg/kg; parallel comparison):
Description: 2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate 0.05% topical formulation (crossover comparison):
Description: 2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.
Study NCT03794778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: PLD 30 mg/m2, i.v.,d1; once every 21days
Study NCT03794778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel 175 mg/m2, i.v.,d1; once every 21days
Study NCT03794778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: carboplatin AUC 5, i.v.,d1; once every 21days,
Study NCT03794778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC 5, i.v.,d1; once every 21days,
Study NCT03326479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Caris Molecular Intelligence Profile
Description: A comprehensive biomarker testing
Study NCT03682354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Nerve Block with PCIA
Description: Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
Study NCT03682354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Description: Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Marijuana (0% THC)
Description: Marijuana cigarette containing 0% THC
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Marijuana (5.5% THC)
Description: Marijuana cigarette containing 5.5% THC
Study NCT00743145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active Marijuana (5.5% THC)
Description: Marijuana cigarette containing 5.5% THC
Study NCT03779360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% topical formulation (crossover comparison):
Description: 2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.